Senseonics Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Senseonics Holdings wird ein Gewinn- und Umsatzwachstum von 0.6% bzw. 31% pro Jahr prognostiziert, während der Gewinn pro Aktie um 3% pro Jahr wachsen soll.

Wichtige Informationen

0.6%

Wachstumsrate der Gewinne

3.0%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.5%
Wachstumsrate der Einnahmen	31.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	17 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

How Much Is Senseonics Holdings' (NYSEMKT:SENS) CEO Getting Paid?

Dec 16

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:SENS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	48	-82	N/A	N/A	3
12/31/2025	36	-76	N/A	N/A	5
12/31/2024	22	-81	N/A	N/A	5
6/30/2024	24	-80	-66	-64	N/A
3/31/2024	23	-81	-71	-71	N/A
12/31/2023	22	-60	-71	-70	N/A
9/30/2023	20	-32	-73	-72	N/A
6/30/2023	18	-68	-70	-70	N/A
3/31/2023	18	57	-66	-66	N/A
12/31/2022	16	142	-67	-66	N/A
9/30/2022	15	215	-61	-61	N/A
6/30/2022	14	318	-60	-60	N/A
3/31/2022	13	34	-60	-60	N/A
12/31/2021	14	-302	-56	-56	N/A
9/30/2021	14	-489	-53	-53	N/A
6/30/2021	11	-555	-52	-52	N/A
3/31/2021	8	-382	-55	-55	N/A
12/31/2020	5	-175	-68	-67	N/A
9/30/2020	10	-109	-94	-94	N/A
6/30/2020	14	-105	-116	-116	N/A
3/31/2020	18	-129	-136	-135	N/A
12/31/2019	21	-116	-137	-136	N/A
9/30/2019	20	-87	-126	-125	N/A
6/30/2019	20	-100	-118	-116	N/A
3/31/2019	19	-101	-102	-100	N/A
12/31/2018	19	-94	-92	-91	N/A
9/30/2018	15	-103	-84	-83	N/A
6/30/2018	12	-88	-72	-72	N/A
3/31/2018	9	-68	N/A	-65	N/A
12/31/2017	6	-59	N/A	-56	N/A
9/30/2017	4	-53	N/A	-50	N/A
6/30/2017	2	-46	N/A	-45	N/A
3/31/2017	1	-46	N/A	-42	N/A
12/31/2016	0	-44	N/A	-38	N/A
9/30/2016	0	-43	N/A	-36	N/A
6/30/2016	0	-40	N/A	-32	N/A
3/31/2016	0	-36	N/A	-28	N/A
12/31/2015	0	-30	N/A	-25	N/A
9/30/2015	0	-26	N/A	-22	N/A
12/31/2014	N/A	-19	N/A	-19	N/A
12/31/2013	0	-19	N/A	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SENS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SENS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SENS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SENSDie Einnahmen des Unternehmens (30.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: SENSDie Einnahmen des Unternehmens (31% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SENS in 3 Jahren voraussichtlich hoch sein wird

Senseonics Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 12%

Senseonics Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024

Consensus revenue estimates decrease by 22%

Consensus EPS estimates fall by 12%, revenue upgraded

Recent updates

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Senseonics Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Senseonics Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration

Senseonics Holdings, Inc. to Report Q1, 2024 Results on May 13, 2024

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024

Consensus revenue estimates decrease by 22%

Senseonics Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Consensus EPS estimates fall by 12%, revenue upgraded

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Independent Non-Management Director recently bought US$162k worth of stock

Price target decreased by 18% to US$1.67

New minor risk - Profitability

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Senseonics Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 29%

Price target increased by 35% to US$2.75

Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Consensus estimates of losses per share improve by 33%

Price target increased by 19% to US$2.50

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 33%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Senseonics Holdings, Inc. Revises Revenue Guidance for Full Year 2022

Senseonics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Senseonics Holdings, Inc. Announces CFO Transition

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analyst expectations

Chief Operating Officer notifies of intention to sell stock

Senseonics Holdings Inc. Announces Positive Coverage Decision for Eversense E3 CGM from Anthem

Investor sentiment improved over the past week

Senseonics Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$2.10

Investor sentiment improved over the past week

Senseonics Holdings, Inc. Announces European Approval of the Next-Generation Eversense E3 Continuous Glucose Monitoring System

Consensus revenue estimates increase by 23%

Price target increased to US$4.25

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Senseonics Holdings, Inc. Announces the First Patient Implant of the Eversense E3 CGM System in the U.S

Independent Non-Management Director notifies of intention to sell stock

Consensus revenue estimates fall by 13%

Full year 2021 earnings: EPS misses analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Price target increased to US$4.17

President recently sold US$1.1m worth of stock

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months

Senseonics Holdings, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Chief Medical Officer & Director notifies of intention to sell stock

Third quarter 2021 earnings released: EPS US$0.096 (vs US$0.099 loss in 3Q 2020)

Independent Non-Management Director exercised options and sold US$410k worth of stock

Independent Non-Management Director recently sold US$457k worth of stock

Consensus forecasts updated

Price target increased to US$2.58

Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.033 loss in 2Q 2020)